HAYA Therapeutics has initiated Phase 1 dosing of HTX-001, an antisense oligonucleotide targeting WISPER RNA to reprogram cardiac fibroblasts and reduce pathological fibrosis in heart failure. Preclinical data support reductions in cardiac fibrosis and functional improvements, with the trial progressing from healthy volunteers to patients with nonobstructive hypertrophic cardiomyopathy.
Key Points
- HTX-001 targets WISPER RNA to reprogram fibrotic cardiac myofibroblasts
- Preclinical results show reduced pathological fibrosis and improved heart function
- Phase 1 trial enrolling healthy subjects before advancing to nHCM patients
Longevity Analysis
Cardiac fibrosis represents a fundamental driver of age-related heart failure and functional decline. By targeting the molecular mechanisms that lock cardiac cells into a fibrotic state—rather than simply managing symptoms—this approach addresses a root cause of circulatory compromise. The progression from preclinical validation to human dosing establishes a pathway toward interventions that restore cellular state and function, potentially extending both healthspan and lifespan in populations with structural cardiac disease.
Original published by LT Wire.